Skye Bioscience Inc. (SKYE): Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Skye Bioscience, Inc. (SKYE) develops cannabinoid-based medicines, leveraging university partnerships to accelerate testing for anti-obesity treatments. The company is establishing a biotechnology hub by introducing innovations in glaucoma therapy. This price chart reflects an EV/EBITDA ratio of 0.00. Management has successfully realigned the research portfolio to match current market trends while maintaining shareholder confidence.

SKYE Skye Bioscience, Inc.: Enterprise Value to EBITDA Ratio in the range 11/23/2025 - 11/14/2026

Metric breakdowns and analytics for Skye Bioscience Inc. (SKYE)

- current price and projected stock value:

Stock Price Skye Bioscience|SKYE - Analyst Consensus Forecast

- stock exchange capitalization data:

Market Value Skye Bioscience, Inc.|SKYE - Value Adjusted for Debt and Cash

- book value of equity indicators:

Net Assets per Single Share Skye Bioscience|SKYE - Company Net Assets|Market Value to Book Value Ratio skyebioscience.com|SKYE - Company Total Asset Base

- debt and solvency information:

- business earnings and investment ratios data:

SKYE - Company Net Income|Projected Future Earnings Skye Bioscience, Inc.|SKYE - Business Payback Period|Future Price to Earnings Skye Bioscience|SKYE - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Skye Bioscience, Inc.|SKYE - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Skye Bioscience|SKYE - Net earnings per share for the last 12 months|Quarterly EPS earnings growth skyebioscience.com|SKYE - Expected net earnings per share growth this year|Earnings growth forecast for next year Skye Bioscience, Inc.

- sales and revenue data:

SKYE - Company Total Revenue|Company Projected Revenue Skye Bioscience, Inc.|SKYE - Market Cap to Revenue Ratio|Forward P/S Multiple Skye Bioscience, Inc.

Initial company analysis:Skye Bioscience SKYE

When screening issuer reliability, it is critical to evaluate business value relative to operating profit. The EV/EBITDA indicator aggregates market capitalization and net debt, dividing them by earnings before interest, taxes, depreciation, and amortization to determine the asset's real value. For Skye Bioscience, Inc. (SKYE), with its liquid balance sheet and biopharmaceutical developments, this metric confirms capital stability. By analyzing the current EV/EBITDA value of Skye Bioscience, Inc. (SKYE), an investor determines whether the market price is fair relative to growth rates.

Competitor analysis

EV/EBITDA Multiple INDV (Indivior Group)|EV/EBITDA Multiple Collegium Corp COLL|CRON - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation CGC (canopygrowth.com)|High Tide (HITI) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Aurora Cannabis Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Achieve Life Sciences, Inc|Anebulo Pharma (ANEB) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization InterCure Ltd. (INCR)|EV/EBITDA Multiple nutriband.com (NTRB)|Nasus Pharma - Enterprise Value to EBITDA Ratio|India Globalization Capital (IGC) - Company Value to EBITDA|MIRA Pharma - EV/EBITDA Multiple|Company Value to EBITDA Flora Growth Inc|IMCC (imcannabis.com) - Enterprise Value to EBITDA Ratio|Adial Pharmaceuticals, Inc. - Business Value to Operating Income Before Depreciation|ARTL (Artelo Biosciences Inc.) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ENSC|EV/EBITDA Multiple TTNP|Total Company Value to Operating Income Before Depreciation Ratio Greenlane Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization InMed Pharmaceuticals INM|akandacorp.com (AKAN) - Company Value to EBITDA|ENVB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Bright Green BGXX|HPCO: EV/EBITDA Multiple